AI Article Synopsis
- Tri-alkoxysalicyl-1,4-diazepan-6-amine (TAoS-DAZA) ligands tagged with 68Ga are being investigated as PET/CT agents for assessing liver function and bile flow.
- A case study involved a patient with liver cancer using 68Ga-tri-methoxysalicyl-(TMoS)-DAZA PET/CT to examine bile duct blockages, particularly at a stent site.
- The procedure went smoothly, allowing for monitoring of bile excretion and suggesting that 68Ga-TAoS-DAZA PET/CT could be useful for dynamic imaging of liver function and diagnosing bile flow issues.
Article Abstract
Tri-alkoxysalicyl-1,4-diazepan-6-amine (TAoS-DAZA) ligands, radiolabelled with 68Ga, have been proposed as PET/CT agents for depiction and quantification of hepatobiliary function and evaluation of bile excretion. In the presented case, a patient with hepatocellulary carcinoma underwent PET/CT with the TAoS-derivate 68Ga-tri-methoxysalicyl-(TMoS)-DAZA to determine the patency of intrahepatic and extrahepatic bile ducts, in particular of a stent in the common bile duct. The PET/CT was performed without complications. Evaluation of bile excretion over time was possible. 68Ga-TAoS-DAZA PET/CT may be an option for dynamic imaging of the excretory hepatic function to visualize the biliary tree and to rule out cholestasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000003719 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!